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ponent score (MCS). Linear regression analysis was conducted with PCS and MCS
scores as dependent variables. Age, race and sex were included as baseline vari-
ables in all models while incorporating Charlson/D’hoore, Elixhauser, and HRQoL-
CI measures one at a time. Adjusted R2 were compared to assess the comparative
performances of risk-adjustment measures. RESULTS: The mean age was 6813
years, with 80.63% non-Hispanic whites. The average PCS and MCS for HF patients
were 45.5312.28 and 30.6411, respectively. HRQoL-CI (R2 0.2083) outperformed
Elixhauser (R2  0.1784) and Charlson/D’hoore (R2  0.1359) in predicting PCS.
Whereas, Elixhauser (R2  0.2184) had the best prediction of MCS compared to
HRQoL-CI (R2  0.1920) and Charlson/D’hoore (R2  0.0918). CONCLUSIONS: No
single comorbidity measure was best in predicting both PCS and MCS in HF pa-
tients; HRQoL-CI performed best in predicting PCS whereas Elixhauser measure
had the best prediction for MCS. Selection of risk adjustment method should be
based on the type of dimension used to evaluate HRQoL.
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IMPACT OF AN INTERACTIVE CARE PLAN ON PATIENT ACTIVATION IN HEART
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OBJECTIVES: Re-hospitalization in heart failure (HF) patients is often the result of a
patient’s inability to adequately self-manage the condition. The objective of this
study is to determine if engaging inpatients in their care through technology is a
solution to improving patient self-management. METHODS: Two hundred seven-
ty-five patients with HF completed the HF interactive care plan while an inpatient
at one of six hospitals throughout the United States. A pretest posttest design was
used to evaluate a patient’s activation using the 13-item Patient Activation Mea-
sure (PAM-13), a valid and reliable instrument to measure a patient’s knowledge,
skill, and confidence to perform self-management of their chronic disease(s). After
completing the baseline PAM-13 following admission for a HF diagnosis, all 275
patients completed a self-paced set of interactive, educational modules through-
out their inpatient stay. These modules were typically completed 3 or 4 days after
admission, and then patients would complete the PAM-13 prior to discharge. The
PAM-13 places individuals into activation levels 1 (lowest) through 4 (highest)
based on an individual’s responses. RESULTS:A two-tailed t-test between baseline
and posttest scores of all participants showed a difference of 0.38 levels of activa-
tion (p .001). Because 168 of the 275 participants were at level 4 on the PAM-13 at
baseline, these individuals were removed and secondary analysis was performed
on the remaining 107 individuals. A two-tailed t-test revealed a difference of 1.05
levels of activation (p 0.001) after patients completed the interactive solution.
CONCLUSIONS: Providing education through an interactive solution while in the
hospital can improve activation scores in HF patients.
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OBJECTIVES: To determine blood pressure goal attainment levels and the factors
influencing them for a low-income, uninsured population with hypertension.
METHODS: A retrospective, cohort study was carried out by reviewing patient
charts at three different sites where patients from CareNet, a Toledo based safety-
net organization, received primary care. Eligible subjects were at least 18 years old
andwere CareNetmembers for aminimumduration of one year between the study
period of January 1, 2003 to December 31, 2008. Descriptive statistics were utilized
to determine goal attainment. Chi-square analysiswas used to determine variables
that had significantly different goal attainment. A binomial logistic regression
model was used to predict goal attainment. Goal attainment at the last recorded
visit served as the dependent variable and was classified as ‘Yes’ and ‘No’ (deter-
mined based on JNC-VII guidelines). Age, gender, race/ethnicity, BMI, tobacco use,
number of primary care visits, and pharmacotherapy treatment were used as pre-
dictor variables. RESULTS: A total of 269 patients were included in the final analy-
sis; 92 of these patients had diabetes while 177 didn’t have diabetes as co-morbid-
ity. The overall goal attainment was found to be 42.39% (n39) in the patients with
diabetes as co-morbidity and 60.45% (n107) among thememberswithout diabetes
as co-morbidity. Chi-square analysis found patients the variables of co-morbidity
(p0.05) and number of visits (p0.01) had significant differences in goal attain-
ment. Patients who had primary care visits between 6-10 times were found to be
significantly more likely (OR3.705; CI: 1.670-8.218) to attain goal when compared
to those who had just 1-5 visits. Notable trends were observed for other variables
(co-morbidity,race/ethnicity,tobacco) but the effect was not significant.
CONCLUSIONS: Goal attainment among CareNet members was found to be com-
parable to other studies and national statistics. Encouraging regular utilization of
primary care services may further improve the clinical outcomes for a population
utilizating a safety-net organization.
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OBJECTIVES: The role of patient- and hospital-level factors in predicting hospital
readmissions in the cardiovascular disease (CVD) setting is established, while the
contribution of community-level factors is less clear. We determine the contribu-
tion of county-level characteristics in predicting discharge and readmission
outcomes. METHODS: This retrospective analysis of hospital discharge data in-
cluded adult patients discharged alive from nonfederal acute care hospitals be-
tween 2000 and 2005. Merged hospital- and county- level data characterized the
admitting hospital in terms of quality of care and the patients’ residence county in
terms of income, crime, medical social services, and private transportation. Multi-
nomial logistic and logistic regression models examined, respectively, the likeli-
hood of 1) 3 discharge outcomes (home, unauthorized discharge, or furthermedical
care), and 2) 31-day same-hospital readmission. The likelihood ratio (LR) test and
Akaike Information Criterion (AIC) compared 3 models: Model 1: patient-level,
Model 2: patient- and hospital-level, and Model 3: patient-, hospital- and
county-level. RESULTS: Application of inclusion criteria resulted in 348,572 dis-
charges with a primary-listed discharge diagnosis of CVD. In the discharge out-
comes models, results from the LR tests that compared Model 2 to Model 1, and
Model 3 to Model 2 were statistically significant (2  773.38, p0.0001; 2 
1346.80, p0.0001), suggesting no data support for the implied restrictions in Mod-
els 1 and 2. The AIC forModels 1, 2, and 3were 309139, 308378, and 307047, favoring
Model 3. In the 31-day readmissionmodels, results from the LR tests that compared
Model 2 to Model 1, and Model 3 to Model 2 also were statistically significant (2 
34.73, p0.0001; 2  89.62, p0.0001). The AIC for Models 1, 2, and 3 were 144041,
144012, and 143931. CONCLUSIONS: Prediction models examining discharge and
readmissions outcomes can benefit from the inclusion of patient-, hospital, and
area (e.g. county) – level measures.
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OBJECTIVES: The aim of this research was to assess the quality of anticoagulation
therapy of patients with atrial fibrillation (AF) in a real life setting and to identify
the causal factors explaining anticoagulation quality deficits. Furthermore, clinical
consequences of suboptimal anticoagulation therapy (strokes, TIA, bleedings, em-
bolism, myocardial infarcts) are identified. METHODS: The INR values as well as
other clinical events concerning AF patients recruited into a prospective cohort
study (observation period of 12 month) were documented at every visit to the
treating doctor. Using the Rosendaal linear trend method, the time in therapeutic
range (TTR) of 2.0-3.0 was estimated. Additionally, the squared INR deviation was
investigated. To identify causes of INR-values below/above 2.0-3.0, a logistic regres-
sion on the basis of a TTR  60% as the dichotomous outcome was conducted.
RESULTS: For 525 patients from 71 study centers, at least two INR values were
available over a median observational period of 228.9 days (SD: 106.1 days). The
average TTR was 68.1 % (SD: 26.3 %). The average deviation of INR value from the
mean of the INR target range (2.5) was 0.44 (SD: 1.29). The results of themultivariate
regression (R20,179) show that themost important factors explaining a poor qual-
ity of anticoagulation therapy are bridging periods and patients self-reported need
of help regarding medication therapy without getting that help. In the group of
patients with a TTR60 %, the occurrence rate of clinical outcomes was higher
(p0.031) than in the group of patientswith a TTR60%.CONCLUSIONS: Labile INR
values lead to negative clinical outcomes. In order to improve the situation, the
main identified causes of poor anticoagulation quality should be addressed.
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OBJECTIVES: Atrial fibrillation (AF) has been identified by the Institute of Medicine
as one of the top research priorities for comparative effectiveness research, yet
there is limited methodological guidance on how to meet the evidentiary needs of
patients, clinicians, and payers. The Center for Medical Technology Policy (CMTP)
managed a stakeholder-driven process to develop an effectiveness guidance doc-
ument that issued guidance for trial designers on study design considerations to
best answer decision-makers’ needs in AF research. METHODS: The AF team re-
viewed the literature and conducted interviews with researchers, patients and
methodologists to scope the project needs. Open-question interviews were con-
ducted with 25 individuals from the clinical research, clinical practice, regulatory,
payer, professional organizations, and patient communities. An eight-person
multi-stakeholder technical working group worked in collaboration with CMTP
staff to establish and refine the recommendations. The methods recommenda-
tions were guided by the objective of achieving an acceptable balance across a
number of desirable dimensions, including internal validity, relevance, feasibility
and timeliness. The document was posted on CMTP’s website for a 30-day public
comment period as part of the broader dissemination and translation strategy.
RESULTS: The final recommendations provide guidance on the design of prospec-
tive studies in Atrial Fibrillation, rationale for their inclusion, specifics on imple-
mentation and data analysis/reporting considerations. The final list included five
research design recommendations, and three priority research areas that would
synergistically benefit stakeholders’ evidentiary needs and improve health
outcomes.CONCLUSIONS:Themeaningful engagement of patients, providers, and
decision makers to prioritize the questions and develop the methods to answer
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them is an essential component of CER. The Atrial Fibrillation methods guidance
was developed in a unique process to improve the future quality of evidence with
a balance between internal validity and external generalizability.
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DRUG APPROVAL STRATEGIES IN GERMANY
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OBJECTIVES: The German legislator introduced early benefit assessments of al-
most all new drug approvals in 2011. Within one year after approval, the pharma-
ceuticalmanufacturer and the Statutory Health Insurance funds negotiate a rebate
based on the early benefit assessment. For each new drug, a common rebate for all
indications is negotiated. Therefore, themanufacturer needs to analyzewhether or
not to seek approval for each potential indication. We aim to analyze the manu-
facturer’s decision. METHODS: We develop a binary decision model to determine
profitability of each indication. Profitability is defined as a positive contribution to
the manufacturer’s global revenue. We apply our model to Ticagrelor as an exam-
ple. Ticagrelor was the first drug that was subject to an early benefit assessment.
The assessment is publicly available and delivers information for four indications.
RESULTS: The approval decision for a specific indication depends on five factors: 1)
Expected benefit as determined by the early benefit assessment; 2) Expected DDDs
in Germany; 3) Willingness for off-label use in the indication in Germany; 4) Ex-
pected DDDs globally; and 5) Impact of the German price on the mean global price.
CONCLUSIONS: The approval decision proves to be complex. Ticagrelor’s early
benefit assessment has shown the important role of the comparator used in the
assessment. The manufacturer named no trials to prove benefit over the adequate
comparators for STEMI (percutaneous coronary intervention) and STEMI (coronary
artery bypass grafting). Willingness for off-label use, however, is high, as currently
observed for Clopidogrel. For such a case, our model shows that it is profitable to
just seek approval for the indication with the greatest additional benefit (unstable
angina/NSTEMI). Based on the best indication, the manufacturer can negotiate a
smaller rebate. Additional revenue is generated if off-label prescriptions are com-
mon in other indications.
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WARNINGS: A CASE STUDY USING AN INTERRUPTED TIME SERIES ANALYSIS
OF THE MEDICARE DATABASE FOR 2006-2008
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OBJECTIVES: To evaluate the impact of Food and Drug Administration (FDA) safety
warning on the utilization rates of thiazolidinedione oral anti-diabetes medica-
tions using an interrupted time series analysis.METHODS: The analysis used data
from the five percent national sample of Medicare Part D beneficiaries. Beneficia-
ries were included if they were diabetic, continuously enrolled in Part D and had
filled a prescription for a thiazolidinedione medication at any time during the
period of January 2006 through December 2008. Beneficiaries were classified each
month into appropriate-use, at risk, and contraindicated groups based on the pres-
ence of certain comorbid conditions. Data were aggregated to monthly utilization
rates. Analyses examined the effects of the May 2007 FDA safety warnings about
the ongoing review of rosiglitazone’s potential to increase cardiovascular risks on
thiazolidinedione utilization rates for the different appropriateness of use catego-
ries using an interrupted time series consisting of 32 data points (13months before
and 19 months after the safety warning). RESULTS: There was an increasing trend
in the total utilization rates of thiazolidinediones before the safety warning. Sig-
nificant decline in drug utilization rates were observed at the end of the study
period for all patient groups on rosiglitazone (relative difference -74.78%, -79.93%,
and -90.21% in appropriate-use, at risk and contraindicated patient groups, respec-
tively). The intervention did not have significant immediate effects on the post-
intervention utilization rates of pioglitazone. However, after the intervention, a
general decline in utilization of thiazolidinediones, including pioglitazone, was
observed. CONCLUSIONS: The initial safety warning about rosiglitazone’s cardio-
vascular safety was effective in decreasing rosiglitazone’s utilization in the tar-
geted population and thus appeared to achieve the desired safety effects. The
safety warning, however, also had spillover effects by reducing utilization of drugs
in other patient cohorts not targeted by the warning.
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OBJECTIVES: Pharmaceutical expenditure is rapidly growing and accounts for
40-50 percent of total medical care expenditures. In order to contain drug expen-
diture growth effectively, we need to understand what the drivers are. This study
aims to answer the question by decomposing the pharmaceutical expenditure
changes into prices, volume, and product substitution effects.METHODS: By using
quarterly drug sales records from 2006-2011 of a large public hospital in Sichuan
province, we analyze the pharmaceutical expenditure changes for two therapeutic
groups: antibiotics (249 products molecules with 2491 records) and cardiovascu-
lar(130 products molecules with1668 records). After standardizing volume and
price recommended by DDD (WHO), a statistic index factor analysis is employed.
Specifically, Laspeyres price index (LPI) and chained LPI are employed to calculate
the price changes with and without entry and exit of products over time. We also
take a closer look at the substitution pattern, including shift among therapeutic
groups, shift between brand and generic drugs, and shift between old and new
drugs. RESULTS: Our results show that both antibiotics and cardiovascular drug
expenditures increased over 30% in the past 5 years. Interestingly, prices are con-
tinuously dropping and the volumes are slightly increasing for both antibiotics and
cardiovascular drugs. Relatively speaking, substitution effect plays the most im-
portant role in expenditure growth. Specifically, proportions of brand-name drugs,
new drugs, and more therapeutic advanced drugs are increasing over time.
CONCLUSIONS: Our study indicates that the key factor that contributes to the
expenditure growth is product substitution effect. Thus, price control policies may
not be an effective way to control the rapid pharmaceutical expenditure growth.
Instead, more attention should be paid on how to control the substitution shifts,
whichmay be caused by prescriber behavior and consumer demand. Further anal-
ysis should also be on the impact of substitution shift on quality of health care.
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OBJECTIVES: To assess the prevalence and determinants of pharmacotherapy in
patients with myocardial infarction. METHODS: The Medical Expenditure Panel
Survey (MEPS) data from 2004 to 2008 were used to conduct a retrospective cross-
sectional study. Study sample included adults  18 years with myocardial infarc-
tion. Pharmacotherapy was defined as the use of aspirin, beta-blockers, statins or
ACEI/ARB. Descriptive characteristics were used to describe the study sample and
utilization patterns. The predictors of pharmacotherapy use were modeled based
on the Andersen Behavior Model using logistic regression. The year variable and
the Charlson’s comorbidity index score (CCI) was also included in the analyses. A
p-value of 0.05was considered to be statistically significant. RESULTS:According to
theMEPS, 55% of the patients received ACEI/ARBs, 68% received beta-blockers, 64%
received statins and 75% received aspirin. Individuals who had a usual source of
healthcare were twice asmore likely to receive ACEI/ARBs (OR: 2.15; CI: 1.20 – 3.84).
Also, patients who were publicly insured (OR: 0.50; CI: 0.28 – 0.90), those who re-
sided in metropolitan region (OR: 0.69; CI: 0.50 – 0.95) and patients having a CCI
score of 2, 3 or 4 were less likely to receive ACEI/ARBs. Females (OR: 0.63; CI: 0.44 –
0.91), blacks (OR: 0.45; CI: 0.30 – 0.66) and individuals who had a CCI score of 10 (OR:
0.22; CI: 0.08 – 0.58) were less likely to receive beta-blockers. Also, as age increased,
the likelihood of taking beta-blockers (OR: 1.22; CI: 1.11 – 1.34) and aspirin (OR: 1.24;
CI: 1.11 – 1.39) increased. Patients who had a usual source of healthcare were 3
times as likely to receive statins (OR: 3.05; CI: 1.53 – 6.10). CONCLUSIONS: Analyses
of national level data revealed suboptimal utilization of evidence-based pharma-
cotherapy for management of myocardial infarction. Concerted efforts are needed
to optimize pharmacotherapy in patients with myocardial infarction.
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OBJECTIVES: Results from several clinical trials have showed that rhythm-control
drugs, which have serious adverse events, have no survival advantage over rate-
control drugs in patients with atrial fibrillation (AF). The objective of the study was
to determine 1) the trends in utilization for rate-control and rhythm-control drugs
from 2001 to 2009; and 2) if the utilization of rhythm-control drugs decreased over
time. METHODS: The physician’s-office and outpatient data components of the
National Ambulatory Medical Care Survey (NAMCS) from 2001 to 2009 were used.
Visits with AF were identified by ICD-9 diagnosis code, ‘427.31’. From these visits,
visits with mentions of rate-control drugs, beta blockers (e.g. metoprolol, propran-
olol, carvedilol, etc.) and non-dihydropyridine calcium channel blockers (vera-
pamil and diltiazem) and visits with mentions of rhythm-control drugs ( e.g. ami-
odarone, disopyramide, propafenone, etc.) were identified using drug codes
provided by NAMCS. Trends in utilization were calculated as total number of visits
with prescriptions divided by total number of visits with AF for each year.
RESULTS: From 2001 to 2009, visits with AF rose from 6.83 million to 11.56 million.
The prescription rate for rate-control drugs increased from 24.28% to 62.31% from
2001 to 2009. The prescription rate for rhythm-control drugs remained the same,
5.31% in 2001 and 5.14% in 2009. The prescription rate for any pharmacotherapy for
AF increased from 29.32% to 67.44% from 2001 to 2009. CONCLUSIONS: The utili-
zation of rhythm-control drugs remained constantwhile that of rate- control drugs
increased from 2001 to 2009. Previously, the treatment approach for AF was to
achieve normal sinus rhythm with rhythm-control drugs and direct current car-
dioversion, rather than use the rate-control drugs. Following the trials on rate-
control and rhythm-control drugs, the use of rate-control strategy increased.
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